Grace Therapeutics, Inc. (GRCE) is set to receive a key FDA decision today, April 23, 2026, on its lead drug candidate GTx-104, an investigational intravenous formulation of nimodipine developed for patients with aneurysmal subarachnoid hemorrhage.
Aneurysmal subarachnoid hemorrhage (aSAH) is a rare but life-threatening form of stroke caused by bleeding on the surface of the brain following the rupture of an aneurysm. It accounts for roughly 5% of all strokes, with an estimated 42,500 patients treated annually in U.S. hospitals. The current standard of care is oral nimodipine, administered for up to 21 days, but its use is often complicated by low blood pressure, inconsistent absorption, and challenges in patients who are unconscious or unable to swallow.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.